New York, NY, April  21, 2026  (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the &#34;Company&#34;) (NASDAQ:AFJK) today announced that on April 17, 2026, it received a notice (the &#34;Notice&#34;) from the Listing

AFJK

AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT

AFJK Faces Nasdaq Compliance Risk Over Late 10-K Filing

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, NY, April  21, 2026  (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the &amp;#34;Company&amp;#34;) (NASDAQ:AFJK) today announced that on April 17, 2026, it received a notice (the &amp;#34;Notice&amp;#34;) from the Listing</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Aimei Health Technology (AFJK) received a notice from Nasdaq for delaying its 10-K report, risking potential delisting. The company has 60 days to file the report or submit a compliance plan, which could grant an extension. Timely action is critical to maintain its listing status and investor confidence.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>AFJK received a notice from Nasdaq regarding late 10-K filing.</li><li>The company has 60 days to regain compliance or face delisting.</li><li>A plan for compliance could extend the deadline by 180 days.</li><li>The company is working on the Annual Report filing.</li><li>No immediate impact on trading, but potential delisting risk exists.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Nasdaq (NDAQ)</strong>: Issuing compliance notice affects AFJK&#039;s market perception.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This situation falls under &#039;Corporate Developments&#039; as it directly relates to compliance with regulatory requirements affecting AFJK&#039;s listing status. The timely filing of financial reports is crucial for investor trust and market stability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Failure to file the 10-K could lead to delisting, impacting shareholder value.</li><li>Positive investor sentiment may hinge on timely filing of compliance documents.</li><li>Market volatility may increase as the compliance deadline approaches.</li><li>A successful compliance plan could stabilize or improve AFJK&#039;s share price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>AFJK&#039;s 10-K was due on March 31, 2026.</li><li>Notice received on April 17, 2026.</li><li>60-day compliance window starts from notice date.</li><li>Plan submission can extend compliance deadline to 180 days.</li><li>No immediate impact on trading at present.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Investors should closely monitor AFJK&#039;s compliance actions over the next 60 days, as failure may result in significant downside.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">New York, NY, April  21, 2026  (GLOBE NEWSWIRE) -- Aimei Health Technology Co., Ltd (the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/AFJK">AFJK</a>) today announced that on April 17, 2026, it received a notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that, as a result of the Company's delay in filing its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the "Annual Report") with the U.S. Securities and Exchange Commission (the "SEC"), the Company is not in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"). The Annual Report was due on March 31, 2026, and the Company filed a Notification of Late Filing on Form 12b-25 with the SEC on April 1, 2026.</p>  <p align="justify">The Notice has no immediate effect on the listing or trading of the Company's securities on Nasdaq. However, if the Company fails to timely regain compliance with the Listing Rule, the Company's securities will be subject to delisting from Nasdaq.</p>  <p align="justify">Under Nasdaq rules, the Company has 60 calendar days from the date of the Notice to either file the Annual Report or submit a plan to Nasdaq to regain compliance with Nasdaq's listing rules. If a plan is submitted and accepted, the Company may be granted up to 180 calendar days from the Annual Report's due date to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.</p>  <p align="justify">The Company is working diligently to complete and file the Annual Report and expects to regain compliance with the Listing Rule.</p>  <p align="justify">This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.</p>  <p align="justify"><b>About Aimei Health Technology Co., Ltd</b></p>  <p align="justify">Aimei Health Technology Co., Ltd is a blank check company incorporated as a Cayman Islands exempted company with limited liability for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The Company's efforts to identify a prospective target business will not be limited to a particular industry or geographic region, although the Company intends to pursue prospective targets focused on healthcare innovation.</p>  <p align="justify"><b>Forward-Looking Statements</b></p>  <p align="justify">This press release contains "forward-looking" statements within the meaning of the federal securities laws. These statements are based on management's current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.</p>  <p align="justify">For investor and media inquiries, please contact:</p>  <p align="justify">Aimei Health Technology Co., Ltd<br></br>10 East 53rd Street, Suite 3001<br></br>New York, NY 10022<br></br>Attention: Junheng Xie<br></br>Email: <a href="https://www.globenewswire.com/Tracker?data=z2_1DhAt7e28WT-oM3qW_bHohD2kS0k4SL8B5RMt1a7Gqpxv9hPEIrgoqHKbBZirxl73KD_X9KT4IExI-Y_SlXHVK19niGz3KQHNKXOwUPsR9tdP1CKVTArL3NWlo6J_" rel="nofollow" target="_blank">Xiejunheng@aimeihealth.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY5Mzg4NCM3NTQ3MTA3IzUwMDEyMDI2Nw=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZWEzMGM1NjYtMmYxZC00ZTFjLWIxMWYtMTg1OWJiYWQ0NDIyLTUwMDEyMDI2Ny0yMDI2LTA0LTIxLWVu/tiny/AIMEI-HEALTH-TECHNOLOGY-CO-LTD.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/d4234cbb-7dfa-43b7-a23a-190fcf662314"><img src="https://ml.globenewswire.com/media/d4234cbb-7dfa-43b7-a23a-190fcf662314/small/screenshot-1-jpg.jpg" border="0" width="150" height="66" alt="Primary Logo"></img></a></p>

Aimei Health Technology (AFJK) received a notice from Nasdaq for delaying its 10-K report, risking potential delisting. The company has 60 days to file the report or submit a compliance plan, which could grant an extension. Timely action is critical to maintain its listing status and investor confidence.

AIMEI HEALTH TECHNOLOGY CO., LTD RECEIVES NASDAQ NOTICE REGARDING DELAYED ANNUAL REPORT

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News